

Corporate Health Physics
Corporate Industrial Hygiene &
Ergonomics
Corporate Occupational Medicine
Corporate Toxicology
3M Medical Department

3M Center, Building 220-2E-02
PO Box 33220
St. Paul, MN 55133-3220
651 733 1110



May 3, 2000

Facsimile

Dr. Jennifer Seed
202-260-1279
USEPA Headquarters
Ariel Rios Building
1200 Pennsylvania Avenue, N. W.
Washington, DC 20460

Re: Serum measurements for Argus Studies 418-013 (through lactation) and 418-015 (during gestation)

Dear Jennifer:

I am including in this fax the two sets of serum perfluorooctanesulfonate measurements from the following two studies:

1. Oral (Gavage) Pharmacokinetic Recovery Study of PFOS in Rats, Argus Laboratories Protocol No. 418-015, 3M Reference No. T-6295.14, *Advanced Bioanalytical Services Study No. FACT-TOX-111.*
2. Oral (Gavage) Pharmacokinetic Study of PFOS in Rats, Argus Laboratories Protocol No. 418-013, 3M Reference No. T-6295.12, *Advanced Bioanalytical Services Study No. FACT-TOX-110.*

The information which I have included relates to the analytical studies indicated above in *bold italics*. Included are pages 10-19 of FACT-TOX-111 and pages 13-23 of FACT-TOX-110. 3M has previously sent the in-life reports and protocols for the analytical phase to the attention of Dr. Hernandez.

I would be happy to meet with you and your EPA colleagues and consultants to provide whatever assistance you may desire in understanding the toxicological information that is being provided.

Please contact me with any questions or if you would like to arrange a meeting.

Sincerely,

John L. Butenhoff, Ph.D., CIH, DABT
Senior Laboratory Manager
Corporate Toxicology
(651) 733-1962

Exhibit
1679

State of Minnesota v. 3M Co.,
Court File No. 27-CV-10-28862

3MA00254228

1679.0001